Immunovia Full Year Report 2020
News provided by
Share this article
LUND, Sweden, Feb. 17, 2021 /PRNewswire/
Immunovia has today published its Full Year Report for January - December 2020. It is available on Immunovia s website. Immunovia is approaching commercial breakthrough: A sales start is planned for the first quarter of 2021. We look forward to helping patients through early detection of pancreatic cancer.
All Immunovia employees are incredibly proud of the progress we have made in 2020, especially with regard to the October 2020 milestone when we were able to document 94 percent accuracy for IMMray™ PanCan-d, the company s first blood test for the diagnosis of pancreatic cancer in the early stages of the disease when it is still possible to conduct surgery. The result opens the way for significantly improved care and survival of patients suffering from this deadly disease.
Immunovia Full Year Report 2020
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Immunovia Full Year Report 2020
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Immunovia publishes link to Webinar No. 3 on IMMray PanCan-d: Verification Study and Clinical Use
LUND, Sweden, Dec. 14, 2020 /PRNewswire/ Immunovia AB (publ) ( Immunovia ) today published the link to the company s third webinar in a series on IMMray PanCan-d, Immunovia s test for early detection of pancreatic cancer. The webinar will cover the IMMray PanCan-d verification study results and its clinical use, including feedback from experts in pancreatic cancer and pancreatic diseases.
Event Details:
Date and Time: December 17, 2020 at 15:00 CET
Moderator for the webinar: CEO Patrik Dahlen
Presenters: Thomas King, MD, PhD; Linda Mellby, PhD, VP R&D; and Laura Chirica, CCO, PhD, Immunovia
About Immunovia
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia s proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique disease biomarker signature .
The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world s largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is currently in the final validation phase. The company aims for a sales start at the end of Q1 2021 with subsequent commercial testing in Q2.